Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis

Andrea Camerini,Giuseppe Luigi Banna,Saverio Cinieri,A. Pezzuto,M. Mencoboni,Francesco Rosetti,A. Figueiredo,P. Rizzo,A. Ricci,L. Langenhoven,A. Santo,Alfredo Addeo,D. Amoroso,F Barata

Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis

2018

Andrea Camerini
Giuseppe Luigi Banna
Saverio Cinieri
A. Pezzuto
M. Mencoboni
Francesco Rosetti
A. Figueiredo
P. Rizzo
A. Ricci
L. Langenhoven
A. Santo
Alfredo Addeo
D. Amoroso
F Barata

Purpose Metronomic oral vinorelbine (MOV) could be a treatment option for unfit patients with advanced non-small cell lung cancer (NSCLC) based on its safety profile and high patient compliance.

Keywords:

General surgery
Vinorelbine
Lung cancer
Medicine
Toxicity
Gastroenterology
non small cell
Immunotherapy
Internal medicine
Anemia
retrospective analysis
treatment options

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations